Stay updated with breaking news from Bill Guyer. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
MENLO PARK, Calif., May 28, 2024 -- Corcept Therapeutics Incorporated , a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic,...
Relacorilant was associated with sustained improvements in hypertension among patients with Cushing syndrome, according to results from the phase 3 GRACE trial.
Relacorilant achieves primary endpoint in phase 3 GRACE trial among patients with hypercortisolism and hyperglycemia, hypertension or both, with sNDA expected in Q3 2024.
Revenue and Earnings Surge Amid Expanding Market Presence
MENLO PARK, Calif., April 22, 2024 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the...